(Q46553509)

English

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

scientific article published in July 2008

Statements

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks (English)
AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit